QLS31905

Phase 3Small molecule

QLS31905 is one of 149 small molecule programs targeting Gastric or Gastroesophageal Junction Adenocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

148

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastric or Gastroesophageal Junction AdenocarcinomaNot yet recruiting

Advanced Malignant Solid TumorsNot yet recruiting

AdenocarcinomaNot yet recruiting

Biliary Tract CancerNot yet recruiting

Pancreatic CancerRecruiting

Gastric or Gastroesophageal Junction AdenocarcinomaPhase 3

Not yet recruiting

Advanced Malignant Solid TumorsPhase 2

Not yet recruiting

AdenocarcinomaPhase 2

Not yet recruiting

Biliary Tract CancerPhase 2

Not yet recruiting

Pancreatic CancerPhase 3

Recruiting

Competition

Competitive Landscape

335 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

QLS31905

Qilu Pharmaceutical Co., Ltd.

Phase 3

1 2

Medrol

Pfizer

Preclinical

1 3

Byetta

AstraZeneca

Preclinical

1 4

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 5

Ayvakit Sprinkle

MMemorial Sloan Kettering Cancer Center

Preclinical

1 6

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 7

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 8

Active Comparator

Moderna

Preclinical

1 9

Sulfonylureas

Eli Lilly

Preclinical

1 10

HS-20093

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Not yet recruiting

Biliary Tract Cancer

NCT07151872

Q4 2027

Phase 2Not yet recruiting

Advanced Malignant Solid Tumors

NCT06446388

Q1 2028

Phase 2Not yet recruiting

Adenocarcinoma

NCT06942767

Q3 2029

Phase 3Not yet recruiting

Gastric or Gastroesophageal Junction Adenocarcinoma

NCT07716449

Clinical

Trials by Indication[1]

Patients With Advanced Solid Tumors2 trials

A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors

Unknown status· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 1/2·NCT06041035·115 enrolled

A Study of QLS31905 in Patients With Advanced Solid Tumors

Unknown status· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 1·NCT05278832·104 enrolled

Biliary Tract Cancer1 trial

Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer

Not yet recruiting· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 2·NCT07151872·120 enrolled

Adenocarcinoma1 trial

Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Not yet recruiting· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 2·NCT06942767·100 enrolled

Advanced Malignant Solid Tumors1 trial

Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors

Not yet recruiting· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 2·NCT06446388·360 enrolled

Pancreatic Cancer1 trial

A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer

Recruiting· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 3·NCT07079228·602 enrolled

1 more indication

Gastric or Gastroesophageal Junction Adenocarcinoma1 trial

A Randomized, Open-label, Multicenter Phase III Clinical Study of QLS31905 in Combination With CAPOX Versus Sintilimab in Combination With CAPOX as First-line Treatment in Patients With Unresectable Locally Advanced or Metastatic CLDN18.2-positive, PD-L1 CPS < 5 Gastric or Gastroesophageal Junction Adenocarcinoma

Not yet recruiting· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 3·NCT07716449·560 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for QLS31905. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — QLS31905 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for QLS31905. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Qilu Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Qilu Pharmaceutical Co., Ltd.

QLS31905

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Q1 2028

Q3 2029

Trials by Indication[1]

Patients With Advanced Solid Tumors2 trials

Biliary Tract Cancer1 trial

Adenocarcinoma1 trial

Advanced Malignant Solid Tumors1 trial

Pancreatic Cancer1 trial

Gastric or Gastroesophageal Junction Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News